Evaluation of epidermal growth factor receptor tyrosine kinase inhibitors combined with chemotherapy: Is there a need for a more rational design?

European Journal of Cancer

Volumn 40, Issue 12, 2004, Pages 1807-1809

  Xu, Jian Ming ^a   Paradiso, Angelo ^b   McLeod, Howard L ^c  

^a Beijing 307 Hospital   (China)

^b NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANGIOGENIC FACTOR; BASIC FIBROBLAST GROWTH FACTOR; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUOROURACIL; GEFITINIB; GEMCITABINE; INTERLEUKIN 8; MONOCLONAL ANTIBODY; OXALIPLATIN; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR; TRANSFORMING GROWTH FACTOR ALPHA; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL; CANCER CHEMOTHERAPY; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CHEMOSENSITIVITY; CLINICAL TRIAL; DNA DAMAGE; HUMAN; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; SHORT SURVEY;

EID: 3843082146     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2004.04.028     Document Type: Editorial

References (28)

1. Mendelsohn J. Targeting the epidermal factor for cancer therapy. J. Clin. Oncol. 20(suppl 15):2002;s1-s13
2. Ciardiello F., Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin. Cancer Res. 7:2001;2958-2970
3. Fukuoka M., Yano S., Giaccone G., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 21:2003;2237-2246
4. Sirotnak F.M., Zakowski M.F., Miller V.A., et al. Efficacy of cytotoxic agents against human tumour xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin. Cancer Res. 6:2000;4885-4892
5. Bruns C.J., Harbison M.T., Davis D.W., et al. Epidermal growth factor receptor antibody blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by anti-angiogenic mechanisms. Clin. Cancer Res. 6:2000;1936-1948
6. Baselga J., Trigo J.M., Bourhis J., et al. Cetuximab (C225) plus cisplatin/carboplatin is active in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) progressing on a same dose and schedule platinum-based regimen. Proc. Am. Soc. Clin. Oncol. 21:2002;226a. [abstr 900]
7. Kris M.G., Natale R.B., Herbst R.S., et al. A phase II trial of ZD1839 ('Iressa') in advanced non-small-cell-lung cancer (NSCLC) patients who failed platinum- and docetaxel-based regimens (IDEAL 2). Proc. Am. Soc. Clin. Oncol. 21:2002;292a. [abstr 1166]
8. Herbst R.S. ZD1839: targeting the epidermal growth factor receptor in cancer therapy. Expert Opin. Inves. Drug. 11:2002;837-849
9. Kroning R., Jones J.A., Hom D.K., et al. Enhancement of drug sensitivity of human malignancies by epidermal growth factor. Br. J. Cancer. 72:1995;615-619
10. Christen R.D., Isonishi S., Jones J.A., et al. Signaling and drug sensitivity. Cancer Metast. Rev. 13:1994;175-189
11. Mattingly R.R., Milstein M., Mirkin B.L. Down-regulation of growth factor-stimulated MAP kinase signaling in cytotoxic drug-resistance human neuroblastoma cells. Cell. Signal. 13(7):2001;499-505
12. Naruse I., Ohmori T., Ao Y., et al. Antitumour activity of the selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Iressa (ZD1839) in an EGFR-expressing multidrug-resistant cell line in vitro and in vivo. Int. J. Cancer. 98:2002;310-315
13. Bunch R.T., Eastman A. Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), anew G2-check point inhibitor. Clin. Cancer Res. 2:1996;791-797
14. Fan S., Smith M.L., Rivet D.J., et al. Disruption of P53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res. 55:1995;1649-1654
15. Ciardiello F., Caputo R., Bianco R., et al. Antitumour effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin. Cancer Res. 6:2000;2053-2063
16. Ciardiello F., Bianco R., Damiano V., et al. Antitumour activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin. Cancer Res. 5:1999;909-916
17. Mendelsohn J., Fan Z. Epidermal growth factor receptor family and chemosensitivity. J. Natl. Cancer Inst. 89:1997;341-343
18. Xu J.M., Azzariti A., Colucci G., et al. Characterization of sequence-dependent synergy between ZD1839 and oxaliplatin. Biochem. Pharmacol. 66:2003;547-559
19. Xu J.M., Azzariti A., Colucci G., et al. The effect of gefitinib (Iressa, ZD1839) in combination with oxaliplatin is schedule-dependent in colon cancer cell lines. Cancer Chemother Pharmacol. 52(6):2003;442-448
20. Kim E.S., Mauer A.M., Fossella F.V.J, et al. A phase II study of Erbitux (IMC-C225), an epidermal factor receptor (EGFR) blocking antibody, in combination with advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 21:2002;293a. [abstr 1168]
21. Burtness B.A., Li Y., Flood W., et al. Phase III trial comparing cisplatin (C). + placebo (P) to C + anti-epidermal growth factor antibody (EGF-R) C225 in patients (pts) with recurrent/metastatic head & neck cancer (HNC) Proc. Am. Soc. Clin. Oncol. 21:2002;226a. [abstr 901]
22. Miller K., Raabe N., Trachtenberg J., et al. ZD1839, an epidermal factor receptor tyrosine kinase inhibitor (EGFR-TKI), is well tolerated in combination with mitoxantrone and prednisone in patients with hormone-refactory cancer (HRPC). Proc. Eur. Soc. Med. Oncol. 91:2002;. [abstr 3270]
23. Soulie P., Trump D., Wilding G., et al. ZD1839, an epidermal factor receptor tyrosine kinase inhibitor (EGFR-TKI), in combination with docetaxel and estramustine in patients with hormone-refactory cancer (HRPC). Proc. Eur. Soc. Med. Oncol. 91:2002;. [abstr 3280]
24. Kosmidis P., Mylonakis N., Nicolaides C., et al. Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial. J. Clin. Oncol. 20:2002;3578-3585
25. Scagliotti G.V., De Marinis F., Rinaldi M., et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J. Clin. Oncol. 20:2002;4285-4291
26. Giaccone G., Johnson D.H., Manegold C., et al. A phase III clinical trail of ZD 1839 ("Iressa") in combination with gemcitabine and cisplatin in chemotherapy-naäive patients with advanced non-small-cell lung cancer (INTACT 1). Proc. Eur. Soc. Med. Oncol. 2:2002;. [abstr 40]
27. Herbst R., Giaccone G., Schiller J.H., et al. ZD 1839 Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trail (INTACT 2). J. Clin. Oncol. 22(5):2004;785-794
28. Rosner G., Stadler W., Ratain M.J. Randomized discontinuation design: application to cytostatic antineoplastic agents. J. Clin. Oncol. 20:2002;4478-4484